⏳ Venous Thromboembolism Anticoagulation Duration Decision
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Venous Thromboembolism Anticoagulation Duration Decision
Provoking-factor type
Bleeding risk
When to use
Use to set anticoagulation duration: short course for major transient triggers, indefinite for cancer or recurrence, and bleeding-risk-dependent for unprovoked VTE.
How it works
Major transient → 3 months. Minor transient → ≥ 3 months, individualized. Cancer → until inactive. Recurrent → extended/indefinite. Unprovoked → extended if low-moderate bleeding (reduced-dose DOAC), stop at 3 months if high bleeding.
Key points
- Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim)
- All VTE receives at least 3 months of anticoagulation regardless of provoking factor.
- Extended courses are periodically reassessed for bleeding risk, benefit, and preference.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.